Can-Fite BioPharma (NYSE:CANF) Upgraded to Hold by StockNews.com

StockNews.com upgraded shares of Can-Fite BioPharma (NYSE:CANF) from a sell rating to a hold rating in a research note published on Tuesday morning.

Separately, EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Can-Fite BioPharma Stock Down 3.8 %

Shares of NYSE:CANF opened at $2.82 on Tuesday. Can-Fite BioPharma has a 12 month low of $1.81 and a 12 month high of $4.69. The company’s 50-day moving average price is $2.29 and its two-hundred day moving average price is $2.51. The firm has a market cap of $9.98 million, a P/E ratio of -1.58 and a beta of 1.41.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its position in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the quarter. Armistice Capital LLC owned about 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.